Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis [STOP-PN2] (NCT06516965)

This study is designed to evaluate the effect of povorcitinib on itch and skin lesions in participants with Prurigo Nodularis. Participants receive either trial medication or a placebo (something that looks like the trial drug but has no effect on the body), both taken orally. The treatment period will approximately be 13 months including safety follow up.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof Johannes S Kern

Key inclusion data

Inclusion: Diagnosis of Prurigo Nodularis for at least 3 months prior to screening; Documented history of treatment failure, demonstrated intolerance, or contraindication to a previous Prurigo Nodularis treatment. Exclusion: Other chronic skin condition other than Prurigo Nodularis; Complex cardiovascular diseases; Albinism.